SCHEMBL1176987

SCHEMBL1176987

CC1CC(=O)c2sc(N3CCOCC3)nc2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 9/20 1.00
PIK3CA P42336 9/20 1.00
PIK3CB P42338 9/20 1.00
PIK3CG P48736 7/20 1.00
ALDH1A1 P00352 3/20 0.51
HTT P42858 1/20 0.49
HIF1A Q16665 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
AR P10275 1/20 0.37
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1177596 0.83 PIK3CD (0.70) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1177411 0.81 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1853780 0.78 PIK3CD (0.64) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1853644 0.78 PIK3CD (0.83) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1176994 0.77 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL303137 0.75 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1177146 0.75 PIK3CD (0.79) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1177102 0.75 PIK3CA (0.74) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL1177167 0.75 PIK3CD (0.74) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1
SCHEMBL304345 0.75 PIK3CA (1.00) PIK3CDPIK3CAPIK3CBPIK3CGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7888344-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2011-02-15 US claimed
EP-1881827-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-09-28 EP disclosed
US-7888344-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2011-02-15 US disclosed
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2008-12-11 US disclosed
EP-1881827-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2008-01-30 EP disclosed
WO-2006114606-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors MAP4K2, PDPK1, DAPK2 PIK3CD 571/4885PIK3CA 402/4885PIK3CB 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.